PET/CT-Assessment of Liver Tumor Ablation

Completed · Not applicable

Conditions studied: Liver Tumor, Liver Neoplasms

In brief

In this research study, the investigators are evaluating whether ammonia PET scans or FDG PET perfusion scans are more useful in helping radiologists determine whether liver tumors were successfully destroyed by the heating or freezing procedures (ablations) than other scans currently available to radiologists, such as CT scans and MRI scans. The currently available scan (usually a CT scan with contrast dye) is not always effective in showing how completely the tumor has been destroyed. The ammonia PET scan is a different way of looking at how much tumor has been destroyed. This study will compare the standard scan (CT scan) with the ammonia PET scan.

Key facts

Study ID

NCT02018107

Run by

Dana-Farber Cancer Institute

People needed

33

Starts

2014-01-01

Expected to finish

2019-02-16

Last updated by the study team

2020-03-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults, 18 years or older
• Referral from an internist, oncologist, or surgeon for liver tumor ablation consultation
• ECOG (Eastern Cooperative Oncology Group) Performance Status < 3
• Liver tumor ablation judged to be appropriate based on clinical assessment in the BWH (Brigham \& Women's Hospital) Tumor Ablation Clinic by the tumor ablation interventional radiologist, per standard clinical practice
• Ability to understand and the willingness to sign a written informed consent document.

You may not qualify if…

• Uncorrectable coagulopathy (due to bleeding risk)
• Pulmonary disease precluding monitored anesthesia care or general anesthesia
• Severe renal insufficiency, EGFR (estimated glomerular filtration rate) < 30
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Childs-Pugh Class C cirrhosis
• Occlusive main portal vein thrombosis
• Presence of biliary-enteric anastomosis (due to risk of biliary infection)
• Pregnant women are excluded (because both CT and PET/CT scans involve the use of ionizing radiation which may pose a potential teratogenic effect on the fetus.)

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.